20 documents found, page 1 of 2

Is Parkinson disease better defined solely by biology or as a clinical–biologic...

The development of Alzheimer's disease (AD) classification and staging systems between 2000 and 2010 marked significant progress in integrating the neurodegenerative process and clinical syndrome. This progress was made possible by improved techniques for measuring amyloid and tau deposition in vivo. Two schemas emerged: the National Institute on Aging and Alzheimer Association (NIA-AA) framework and the Intern...

Somatic CAG repeat expansion in blood associates with biomarkers of neurodegene...

Huntington's disease (HD) is an autosomal dominant neurodegenerative disease with the age at which characteristic symptoms manifest strongly influenced by inherited HTT CAG length. Somatic CAG expansion occurs throughout life and understanding the impact of somatic expansion on neurodegeneration is key to developing therapeutic targets. In 57 HD gene expanded (HDGE) individuals, ~23 years before their predicted...

Modeling disease progression and placebo response in huntington disease: insigh...

Background and objectives: Huntington disease is a rare neurodegenerative disorder with no disease-modifying therapies. This study aimed to quantify longitudinal changes in Unified Huntington's Disease Rating Scale (UHDRS) scores and evaluate their susceptibility to placebo response, enhancing our understanding of disease progression and ability to optimize future trials. Methods: We used data from the Enroll-H...

Update on treatments for Parkinson's disease motor fluctuations: an internation...

Objective: To update evidence-based medicine recommendations for treating motor fluctuations of Parkinson's disease (PD). Background: The International Parkinson and Movement Disorder Society (MDS) Evidence Based Medicine in Movement Disorders Committee recommendations for the treatments of PD were first published in 2002 and regularly updated. The current review uses a new methodology, including the Cochrane R...

Huntington disease: update on ongoing therapeutic developments and a look towar...

Huntington’s disease (HD) is a genetic condition inherited in an autosomal dominant pattern characterized by neurodegeneration. The root cause of HD is a CAG tract expansion occurring in exon 1 of the huntingtin (HTT) gene. This mutation sets in motion a series of detrimental events that progressively lead to neuronal death and structural changes, mainly within the central nervous system but also affecting othe...

FDA boosts the Progressive Supranuclear Palsy Rating Scale!

Gewily et al report on the significant modification of the well-established progressive supranuclear palsy rating scale (PSPRS), a process that was prompted and guided by feedback from the United States Food and Drug Administration (FDA). This study comprehensively compared the original (full PSPRS, 28 items) and the shortened only and shortened and rescored (PSPRS-10 and rPSPRS-10) versions of the PSPRS using ...

A MDS evidence‐based review on treatments for Huntington's Disease

Background: Huntington's disease (HD) is a rare neurodegenerative disorder with protean clinical manifestations. Its management is challenging, consisting mainly of off-label treatments. Objectives: The International Parkinson and Movement Disorder Society commissioned a task force to review and evaluate the evidence of available therapies for HD gene expansion carriers. Methods: We followed the Grading of Reco...

Interpretation of chronic pain clinical trial outcomes : IMMPACT recommended co...

Interpreting randomized clinical trials (RCTs) is crucial to making decisions regarding the use of analgesic treatments in clinical practice. In this article, we report on an Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) consensus meeting organized by the Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks, the purpose...

Validation of a Novel, Sensitive, and Specific Urine-Based Test for Recurrence ...

Bladder cancer (BC), the most frequent malignancy of the urinary system, is ranked the sixth most prevalent cancer worldwide. Of all newly diagnosed patients with BC, 70-75% will present disease confined to the mucosa or submucosa, the non-muscle-invasive BC (NMIBC) subtype. Of those, approximately 70% will recur after transurethral resection (TUR). Due to high rate of recurrence, patients are submitted to an i...

Neuromelanin magnetic resonance imaging of the Substantia Nigra in LRRK2-relate...